BioSpace News Archive

GE HealthCare announced the launch of Vscan Air SL – a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”) announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, will discuss novel proof of concept data in his presentation, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023.

A new paper that presents, for the first time, the complete sequences of multiple human Y chromosomes from lineages from around the globe provides an essential step forward in understanding the roles of the Y chromosome in human evolution and biology.

The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today presented results from ATHENS, a retrospective real-world data study, at the European Society of Cardiology (ESC) Congress 2023 showing that switching from Eliquis® (apixaban) to rivaroxaban in Non-Valvular Atrial Fibrillation (NVAF) patients was associated with a higher risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those who continued Eliquis.

Kerecis® Shield™, the new fish-skin wound-treatment product family for private doctors’ clinics, has been approved by multiple leading Medicare Administrative Contractors.

Assertio Holdings, Inc. announced that effective August 21, 2023, the Compensation Committee of the Company’s Board of Directors granted one newly-hired employee a total of 11,585 restricted stock units and 12,745 stock options.

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., a clinical-stage biotech company committed to advancing antiviral therapies and vaccines, with a primary focus on achieving a functional cure for chronic hepatitis B infection, announced the U.S. Food and Drug Administration has granted clearance for the Investigational New Drug application for a clinical trial on AHB-137.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September.

Zhiyi Biotech announced that the first three subjects have been dosed in the U.S. Phase 1 clinical trial of SK10, an innovative heat-killed Bacteroides fragilis product developed by Zhiyi Biotech for Chemotherapy-induced Diarrhea.

XyloCor Therapeutics, Inc. presented results from the Phase 2 portion of its Phase 1/2 clinical trial of its lead gene therapy candidate XC001 for refractory angina at the European Society of Cardiology Congress 2023.